The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Atrys Health's Revenue for the
six
months ended in Dec. 2025 was €69.9 Mil. Atrys Health's average Accounts Receivable for the
six
months ended in Dec. 2025 was €45.6 Mil.
Hence, Atrys Health's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.53.
Atrys Health (XMAD:ATRY) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Atrys Health Receivables Turnover Related Terms
Atrys Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Atrys Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Atrys Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Atrys Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrys Health (XMAD:ATRY) has a Receivables Turnover of 1.53 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #548 out of 839 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Atrys Health's Receivables Turnover too high?
Atrys Health's current Receivables Turnover is 1.53. The Biotechnology industry median Receivables Turnover is 5.27. Atrys Health's value of 1.53 is 71% below this industry median. Based on the distribution chart, Atrys Health ranks #548 out of 839 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #548 out of 839 companies for Receivables Turnover. This places Atrys Health in the lower half of its industry. The industry median Receivables Turnover is 5.27. Atrys Health's value of 1.53 is 71% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrys Health's current Receivables Turnover of 1.53 is 71% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Atrys Health and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrys Health's current Receivables Turnover is 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.13, compared to a current price of €2.58 — trading 17.7% below its estimated fair value. The current Receivables Turnover is 1.53 and 71% below the Biotechnology industry median of 5.27. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Receivables Turnover is 1.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.58 is trading 17.7% below its estimated GF Value™ of €3.13.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
Receivables Turnover: 1.53
GF Value™: €3.13 vs. price of €2.58 (17.7% below fair value)
Industry Position: 71% below the Biotechnology median (#548 of 839)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score
Get the complete analysis for XMAD:ATRY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
